19
DEC
2017
NW Bio Announces Regulation D Offering for Accredited Investors
Comments : Off
Financing Responds to Shareholder Requests Following Recent Series A Preferred Stock Financing BETHESDA, Md., December 19, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) — (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it is commencing a general solicitation Regulation D offering to accredited investors. The Offering will remain open for execution... Read More